Hepatic Tumor Clinical Trial Landscape Strengthens as 75+ Companies Accelerate Innovation in Emerging Therapies | DelveInsight

Hepatic Tumor companies include Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., and Eureka Therapeutics Inc, among others.
DelveInsight's latest report, "Hepatic Tumor Pipeline Insight 2026," delivers an extensive evaluation of the evolving therapeutic landscape, highlighting the contributions of more than 75 companies actively developing over 75 pipeline candidates for hepatic tumors. The report offers a deep dive into both clinical and preclinical drug candidates, along with a comprehensive assessment based on product type, development stage, route of administration, and molecular classification. It also sheds light on discontinued and inactive programs within this domain.

Explore the latest advancements and emerging treatment options in the Hepatic Tumor pipeline: https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight

Key Highlights from the Hepatic Tumor Pipeline Report

* On February 20, 2026, Crinetics Pharmaceuticals Inc. announced a Phase III clinical trial assessing the efficacy and safety of paltusotine in adult patients with carcinoid syndrome. The study design includes an 11-week screening period, a 16-week randomized double-blind phase, a 104-week open-label extension, and a 4-week follow-up phase.
* On February 09, 2026, Stanford University initiated a Phase II trial evaluating real-time MRI-guided adaptive stereotactic ablative radiotherapy for liver cancers, utilizing a single-session, simulation-free approach.
* DelveInsight's findings highlight a dynamic and competitive pipeline landscape, with over 75 organizations advancing more than 75 therapeutic candidates aimed at treating hepatic tumors.
* Prominent players in this space include Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., and Eureka Therapeutics Inc, among others.
* Key investigational therapies gaining attention include Atezolizumab, Bevacizumab (15 mg/kg), Tiragolumab, NIK-333 (peretinoin), Sorafenib, SonoVue Registered , Talaporfin sodium, NV1020, and Pemetrexed.

Gain detailed insights into clinical trials, pipeline drugs, and leading innovators: Hepatic Tumor Treatment Drugs [https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Emerging Drug Profiles in Hepatic Tumor Treatment

Namodenoson - Can Fite Biopharma

Namodenoson is an orally administered small molecule targeting the A3 adenosine receptor (A3AR). It is being developed for multiple oncology indications, including hepatocellular carcinoma, pancreatic cancer, and metabolic-associated steatohepatitis (MASH). Currently in Phase III trials, it represents a promising late-stage candidate for liver cancer treatment.

MTL-CEBPA - MiNA Therapeutics

MTL-CEBPA is an innovative RNA-based therapy designed to restore normal levels of the C/EBP- protein, thereby reducing immune suppression in myeloid cells. Developed as part of combination cancer therapies, it is currently being evaluated in Phase II clinical studies.

Amivantamab - Janssen Research & Development, LLC

Amivantamab is a fully human bispecific antibody targeting EGFR and MET mutations. It works through immune cell-directed activity and antibody-dependent cytotoxicity mechanisms. The therapy is currently in Phase II trials for hepatic tumors.

Fostroxacitabine bralpamide - Medivir AB

This next-generation chemotherapy agent selectively delivers cytotoxic compounds to tumor cells while sparing healthy tissue. Acting as a nucleotide DNA polymerase inhibitor, it is being studied in Phase I/II trials and is administered orally.

ETN101 - Etnova Therapeutics Corp.

ETN101 is a multi-target tyrosine kinase inhibitor designed to treat hepatocellular carcinoma. It blocks key signaling pathways such as PI3K/AKT and RAS-MAPK and targets FLT3, KIT, VEGFR2, and PDGFRB. Currently in Phase I trials, it shows potential as both a first-line and follow-up therapy.

Comprehensive Insights Offered by the Report

* In-depth profiles of companies actively engaged in hepatic tumor drug development, along with their respective therapeutic portfolios
* Segmentation of pipeline candidates into early-, mid-, and late-stage development categories
* Overview of both active and inactive programs within the hepatic tumor pipeline
* Evaluation of drugs based on mechanism of action, route of administration, molecular type, and therapeutic approach (monotherapy vs. combination therapy)
* Detailed analysis of strategic collaborations, licensing agreements, and funding activities shaping future market growth

Explore the next generation of therapies and clinical advancements: New Hepatic Tumor Drugs [file:///E:/Ankit%20Laptop%20Data%20C%20Drive/Desktop/ABNewswire/Press%20Releases/:%20https:/www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight]

Key Companies in the Hepatic Tumor Space

The competitive landscape features a diverse mix of biotechnology firms and pharmaceutical companies, including Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., and Eureka Therapeutics Inc, among others.

Therapeutic Segmentation

By Route of Administration:

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical

By Molecule Type:

* Monoclonal antibodies
* Peptides
* Polymers
* Small molecules
* Gene therapies

Gain expert insights on market drivers, barriers, and future outlook: Hepatic Tumor Market Drivers and Barriers [https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Scope of the Report

* Geographical Coverage: Global
* Pipeline Therapies Covered: Atezolizumab, Bevacizumab, Tiragolumab, NIK-333, Sorafenib, SonoVue Registered , Talaporfin sodium, NV1020, Pemetrexed, and others
* Therapeutic Assessment: Monotherapy, combination therapy, and hybrid approaches
* Development Stages Covered: Discovery, preclinical, Phase I, Phase II, and Phase III

Download the complete report to uncover key opportunities and unmet needs in the hepatic tumor market: Hepatic Tumor Companies, Key Products and Unmet Needs - https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight [https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

* Introduction
* Executive Summary
* Disease Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late-, Mid-, and Early-Stage Products
* Comparative Analyses
* Key Companies and Products
* Unmet Needs
* Market Drivers and Barriers
* Future Outlook and Analyst Perspectives
* Appendix

About DelveInsight

DelveInsight is a globally recognized market research and consulting firm specializing in the healthcare and life sciences sectors. The company provides actionable insights and data-driven analysis to support strategic decision-making. With a team of seasoned experts, DelveInsight delivers customized solutions that help clients stay competitive and capitalize on emerging market opportunities.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hepatic-tumor-clinical-trial-landscape-strengthens-as-75-companies-accelerate-innovation-in-emerging-therapies-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.